• Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition

    • September 7, 2026
    • Posted by: Megan Foster
    • Category: Business plans
    No Comments

    CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Sept. 6, 2026 /PRNewswire/ — Today, shares of Harbour BioMed (the “Company”; HKEX: 02142.HK) were officially included in the eligible shares list of the Stock Connect. Effective immediately, qualified investors in mainland…

    read more

  • Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults

    • September 6, 2026
    • Posted by: Victoria Reynolds
    • Category: Economics
    No Comments

    — Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection —- Robust neutralizing antibody responses across…

    read more

  • Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

    • September 6, 2026
    • Posted by: Victoria Reynolds
    • Category: Economics
    No Comments

    SHANGHAI, Sept. 6, 2026 /PRNewswire/ — Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up…

    read more